Efficacy of Venetoclax Combination Therapy in Elderly Patients with Acute Myeloid Leukemia
Objective To explore the efficacy of venetoclax(VEN)combination therapy in elderly patients with acute myeloid leukemia(AML).Methods Eighty-two elderly AML patients admitted to Puyang City Anyang District Hospital from January 2020 to March 2023 were retrospectively selected.All patients were treated with VEN in combination with hypomethylating agents(HMAs).The treatment response in patients was analyzed.Results Among the selected patients,there were 51 therapy-naive patients and 31 re-treated patients.Of the therapy-naive patients,64.71％(33/51)received VEN in combination with azacitidine and the remaining 35.29％(18/51)were treated with VEN in combination with decitabine.Of the re-treated patients,25(80.65％)received VEN in combination with azacitidine and the remaining 6(19.35％)patients were treated with decitabine.There were 39 complete response patients,accounting for 47.56％,19 incomplete response patients,accounting for 23.17％,5 partial response patients,accounting for 6.10％.The overall response rate was 76.83％,and the negative rate of minimal residual disease was 37.80％.The patient was followed up for 2-40 months,with a median follow-uptime of 19 months.As of April 30,2023,out of 82 patients,62(75.61％)survived,8(9.76％)died,and 2(2.44％)patients were lost to follow-up.The total incidence of grade 3 or greater adverse reactions was 87.80％,including 94.12％(48/51)in therapy-naive patients and 96.77％(30/31)in re-treated patients.Conclusion The VEN combination therapy achieves good treatment response in elderly AML patients,while it is associated with a high incidence of adverse effects.
万方数据
维普
